申请人:Cassella Aktiengesellschaft
公开号:US04598079A1
公开(公告)日:1986-07-01
Aryl-substituted piperazinones and their physiologically-acceptable acid-addition salts have a useful nootropic action. They are administered enterally or parenterally in conventional dosage forms.
芳基取代哌嗪酮及其生理上可接受的酸盐具有有用的智力增强作用。它们以常规剂型肠内或静脉内给药。